<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>SHP1705 clinical trials &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/shp1705-clinical-trials/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 12:29:40 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>SHP1705 clinical trials &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Novel Compound Targets Cellular Circadian Clock to Combat Glioblastoma</title>
		<link>https://bioengineer.org/novel-compound-targets-cellular-circadian-clock-to-combat-glioblastoma/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 13 May 2025 00:50:14 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[circadian clock-targeted therapy]]></category>
		<category><![CDATA[CRY2 activation glioblastoma]]></category>
		<category><![CDATA[glioblastoma stem cell disruption]]></category>
		<category><![CDATA[precision medicine neuro-oncology]]></category>
		<category><![CDATA[SHP1705 clinical trials]]></category>
		<guid isPermaLink="false">https://bioengineer.org/novel-compound-targets-cellular-circadian-clock-to-combat-glioblastoma/</guid>

					<description><![CDATA[A groundbreaking new compound named SHP1705 is generating excitement in the fight against glioblastoma, the most aggressive and lethal brain tumor diagnosed in adults today. Building on years of research into circadian biology, this novel agent specifically targets circadian clock proteins that glioblastoma stem cells exploit to fuel their relentless growth and survival. Unlike previous [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">244625</post-id>	</item>
	</channel>
</rss>
